Delcath Systems Future Growth

Future criteria checks 5/6

Delcath Systems is forecast to grow earnings and revenue by 69.1% and 41.7% per annum respectively while EPS is expected to grow by 71.6% per annum.

Key information

69.1%

Earnings growth rate

71.6%

EPS growth rate

Medical Equipment earnings growth	17.7%
Revenue growth rate	41.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	27 Aug 2024

Recent future growth updates

Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 07

Recent updates

Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?

Aug 27

Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 07

Earnings and Revenue Growth Forecasts

NasdaqCM:DCTH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	134	41	45	45	6
12/31/2025	73	-5	11	14	6
12/31/2024	33	-38	-16	-16	6
6/30/2024	12	-56	-32	-31	N/A
3/31/2024	5	-50	-37	-37	N/A
12/31/2023	2	-48	-31	-31	N/A
9/30/2023	2	-45	-30	-30	N/A
6/30/2023	3	-34	-27	-26	N/A
3/31/2023	3	-37	-23	-23	N/A
12/31/2022	3	-37	-25	-25	N/A
9/30/2022	4	-33	-24	-24	N/A
6/30/2022	4	-32	-24	-23	N/A
3/31/2022	4	-28	-25	-24	N/A
12/31/2021	4	-26	-23	-23	N/A
9/30/2021	2	-27	-22	-22	N/A
6/30/2021	2	-25	-22	-21	N/A
3/31/2021	2	-23	-23	-22	N/A
12/31/2020	2	-24	-24	-23	N/A
9/30/2020	2	-5	-24	-23	N/A
6/30/2020	2	-7	-31	-31	N/A
3/31/2020	2	-9	-26	-26	N/A
12/31/2019	2	-9	-24	-24	N/A
9/30/2019	2	-32	-20	-20	N/A
6/30/2019	3	-34	-11	-11	N/A
3/31/2019	3	-34	-11	-11	N/A
12/31/2018	3	-19	-15	-15	N/A
9/30/2018	3	-28	-17	-17	N/A
6/30/2018	3	-32	-17	-17	N/A
3/31/2018	3	-27	N/A	-18	N/A
12/31/2017	3	-46	N/A	-15	N/A
9/30/2017	3	-34	N/A	-15	N/A
6/30/2017	2	-23	N/A	-15	N/A
3/31/2017	2	-27	N/A	-14	N/A
12/31/2016	2	-18	N/A	-14	N/A
9/30/2016	2	-15	N/A	-15	N/A
6/30/2016	2	-16	N/A	-14	N/A
3/31/2016	2	-13	N/A	-16	N/A
12/31/2015	2	-15	N/A	-16	N/A
9/30/2015	2	-13	N/A	-15	N/A
6/30/2015	1	-15	N/A	-16	N/A
3/31/2015	1	-16	N/A	-15	N/A
12/31/2014	1	-17	N/A	-16	N/A
9/30/2014	1	-19	N/A	-18	N/A
6/30/2014	1	-22	N/A	-21	N/A
3/31/2014	1	-23	N/A	-28	N/A
12/31/2013	1	-30	N/A	-34	N/A
9/30/2013	1	-36	N/A	-38	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DCTH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: DCTH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DCTH is expected to become profitable in the next 3 years.

Revenue vs Market: DCTH's revenue (41.7% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: DCTH's revenue (41.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if DCTH's Return on Equity is forecast to be high in 3 years time

Delcath Systems Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 14%

Consensus revenue estimates increase by 13%

Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Consensus revenue estimates increase by 11%

Price target increased by 8.1% to US$20.80

Forecast breakeven date pushed back to 2026

Recent updates

Consensus EPS estimates fall by 14%

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?

Consensus revenue estimates increase by 13%

Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Delcath Systems Regains Compliance with the Audit Committee Composition Requirements

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

New major risk - Financial position

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Consensus revenue estimates increase by 11%

Price target increased by 8.1% to US$20.80

Delcath Systems, Inc. to Report Q1, 2024 Results on May 14, 2024

Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Forecast breakeven date pushed back to 2026

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?

No longer forecast to breakeven

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Insufficient new directors

Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates fall by 18%

Independent Chairman recently bought US$51k worth of stock

CEO & Director exercised options to buy US$171k worth of stock.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

New major risk - Shareholder dilution

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Consensus revenue estimates decrease by 46%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought US$55k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$18.20

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems Q2 2022 Earnings Preview

CEO & Director recently bought US$250k worth of stock

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding

Delcath Systems to raise $5M in stock and warrants offering

Delcath Systems: Revisiting A $5 Lottery Ticket

Price target decreased to US$21.20

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Price target decreased to US$22.00

Delcath Systems, Inc., Annual General Meeting, May 04, 2022